ClinicalTrials.gg
CompletedNCT03984097Updated Apr 9, 2026

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

A Phase 1 interventional study of TAK-079 and Lenalidomide in Multiple Myeloma, sponsored by Takeda. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Multiple Myeloma by Takeda — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Myeloma · Takeda.

Enrollment
24th of 38
50 · median 61
Started
2019
with 2 others
Phase 1
12 of 54
none open now
Registered
42nd of 54
by date

Among the 54 studies in Multiple Myeloma by Takeda, this one is the 24th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2019, is one of 12 in phase 1, and was the 42nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 54 studies in Multiple Myeloma by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Multiple Myeloma by Takeda, or all of them as a file.
02

Study summary

The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen. The purpose of the safety/access cohort is to provide continued access to TAK-079 to participants previously enrolled to a TAK-079 parent study and to evaluate the long-term safety profile of TAK-079.

Read the detailed description

Treatment phase drug being tested in this study is called TAK-079. TAK-079 is being tested to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) when added to 1 of 2 standard backbone regimens (LenDex or VRd) with newly diagnosed NDMM for whom stem cell transplantation (SCT) is not planned as initial therapy.

The study will enroll approximately 36 participants. Participants will be non-randomly assigned to one of the two treatment groups in the original study or Treatment Phase:

  • TAK-079 and LenDex
  • TAK-079 and VRd

All enrolled participants will have the opportunity to complete the treatment therapy and then enter the Extension study for as long as participants continue to derive benefit. Safety Extension Phase participants who have previously received and tolerated TAK-079-based parent study will continue to the extension study. The study will also evaluate the long-term safety profile of TAK-079. Participants will continue to receive TAK-079 and, if applicable, SOC backbone therapy as per the parent study.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Drug Therapy
  • TAK-079
  • CD38
  • Monoclonal Antibody
  • Lenalidomide
  • Bortezomib
  • Pomalidomide
  • Velcade
  • Stem Cell Transplant
  • Neoplasms, Plasma Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have previously untreated multiple myeloma (MM) as defined by the IMWG criteria requiring treatment according to the investigator.
  2. Are appropriate candidates for either the VRd or Rd backbone antimyeloma therapy according to the investigator.
  3. Must have defined by at least 1 of the following:

    • Serum M-protein >=1 gram per deciliter (g/dL) (>=10 gram/liter [g/L]).
    • Urine M-protein >=200 mg/24 hours.
    • Serum FLC assay: involved FLC level >=10 mg/dL (>=100 milligram per liter [mg/L]) provided the serum FLC ratio is abnormal.
  4. Participants receiving lenalidomide must be able to take concurrent prophylactic anticoagulation per standard clinical practice as directed by the investigator.
  5. >3 months.
  6. (ECOG) performance status score less than or equal to (\<=) 2.

Inc Criteria for Participants in the Safety/Access Cohort (only):

Participants previously treated with TAK-079 therapy in a Takeda-sponsored TAK-079 parent study. Participants will be eligible to enter this cohort when:

1. The parent study is closed, planned to be closed, or has met its primary objectives.

Exclusion criteria

Exclusion (Exc) Criteria:

  1. Prior systemic therapy for MM.

    o treatment with bisphosphonates or a single course of does not disqualify the participant (the maximum dose of corticosteroids should not exceed the equivalent of 160 mg [for example, 40 milligram per day (mg/d) for 4 days] of dexamethasone).

  2. Current participation in another interventional study, including other clinical trials with agents (including investigational vaccines or investigational medical device) within 4 weeks of the first dose of TAK-079 or any agent in the backbone regimen and throughout the duration of this trial.
  3. Prior radiation therapy within 14 days of the first dose of TAK-079 or any backbone regimen agents.

    NOTE: Prophylactic localized ("spot") radiation for areas of pain is allowed.

  4. Major surgery within 4 weeks before Cycle 1 Day 1 (kyphoplasty is not considered major surgery). Participants should be fully recovered from any surgically related complications.
  5. Plasmapheresis within 28 days of randomization.
  6. If plasmacytoma is the only measurable parameter for assessing disease response, participant is not eligible because of difficult response evaluation.
  7. Clinical signs of meningeal involvement of MM exhibited during screening.
  8. Serum positive for (HIV) or active virus (HBV) or virus (HCV) infection.
  9. Known severe allergic or anaphylactic reactions to human recombinant proteins or used in the TAK-079 formulation or agents in the backbone regimen (lenalidomide, bortezomib, dexamethasone) as per the respective prescribing information or for TAK-079, as outlined in the current investigator's brochure (IB).
  10. Systemic infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of TAK-079 or any agent in the backbone regimen. Urinary tract infection is not considered a systemic infection.
  11. A 12-lead (ECG) showing a corrected by Frederica's formula (QTcF) >470 milliseconds. If a machine reading is above this value, the ECG should be reviewed by a qualified reader and confirmed on a subsequent ECG.
  12. Diagnosis of primary amyloidosis, Waldenstrom's disease, monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) per IMWG criteria or standard diagnostic criteria, plasma cell leukemia (according to the World Health Organization [WHO] criterion: >=20% of cells in the peripheral blood with an absolute plasma cell count of more than 2 *10\^9/L), polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS syndrome), myelodysplastic syndrome, or myeloproliferative syndrome.
  13. History of myelodysplastic syndrome or another other than MM, except for the following: any malignancy that has been in complete remission for 2 years, adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer (Gleason score \<=6 without known disease and with no requirement for therapy, or requiring only hormonal therapy and stable prostate-specific antigen for >=1 year before initiation of study therapy), breast carcinoma in situ with full surgical resection, and treated medullary or papillary thyroid cancer.

Exc Criteria for Participants in the Safety/Access Cohort

1. Participants meeting any of the criteria for treatment discontinuation in the parent study.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Treatment Phase: TAK-079 and LenDex

    TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with lenalidomide, orally, once daily for 21 days and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until progressive disease (PD) or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are greater than (\>) 75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.

    Drug: TAK-079 · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Pomalidomide

  • Experimental
    Treatment Phase: TAK-079 and VRd

    TAK-079 subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with bortezomib, subcutaneously, once on Days 1, 8, and 15, for a maximum of 8 cycles, lenalidomide, orally, once daily for 21 days, and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until PD or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are \>75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.

    Drug: TAK-079 · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Pomalidomide

  • Experimental
    Safety Extension Phase: TAK-079 and, if applicable, backbone therapy (LenDex, VRd, or PomDex)

    TAK-079 dosing and, if applicable, backbone therapy will be administered as per the schedule outlined in the parent study.

    Drug: TAK-079 · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Pomalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Phase: RP2D of TAK-079

    RP2D of TAK-079 along with lenalidomide-dexamethasone (LenDex) or TAK-079 along with bortezomib, lenalidomide, and dexamethasone (VRd) will be based on number of participants with dose limiting toxicity (DLT). DLTs will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.

    Time frame: Up to Cycle 1 (Cycle length is equal to [=] 28 days)

  2. Safety Extension Phase: Number of Participants Reporting one or More Serious Adverse Events (SAEs)

    Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)

  3. Safety Extension Phase: Number of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)

    Adverse event (AE) Grades will be evaluated as per NCI CTCAE, version 4.03.

    Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)

  4. Safety Extension Phase: Number of Participants Who Require Dose Modification

    Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)

  5. Safety Extension Phase: Number of Participants With TEAEs Leading to Treatment Discontinuation

    Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)

Secondary outcomes

  1. Treatment Phase: Overall Response Rate (ORR)

    ORR based on International Myeloma Working Group (IMWG) Uniform Response Criteria, is defined as the percentage of participants who achieved a PR or better during the study. PR is defined as greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein, and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligram per 24 hours (mg/24 h). If serum and urine M protein are not measurable, \>=50% decrease in difference between involved and uninvolved free light chain (FLC) levels is required in place of M protein criteria.

    Time frame: Up to 2 years

  2. Treatment Phase: Number of Participants Reporting one or More TEAEs and SAEs

    Time frame: From first dose up to 30 days after the last dose of study drug (up to 2 years)

  3. Treatment Phase: Number of Participants With Grade 3 or Higher TEAEs

    AE Grades will be evaluated as per NCI CTCAE, version 4.03.

    Time frame: From first dose up to 30 days after the last dose of study drug (up to 2 years)

  4. Treatment Phase: Number of Participants with TEAEs Leading to Treatment Discontinuation

    Time frame: From first dose up to 30 days after the last dose of study drug (up to 2 years)

  5. Treatment Phase: Number of Participants With AEs Leading to On-study Deaths

    Time frame: From screening up to 30 days after the last dose of study drug (up to 2 years)

07

Study locations

9 sites
  • Alabama Oncology
    Birmingham, Alabama 35211, United States
  • Pacific Cancer Care
    Monterey, California 93940, United States
  • American Oncology Partners of Maryland, PA
    Bethesda, Maryland 20817, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Good Samaritan Hospital
    Cincinnati, Ohio 45220, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Froedtert Hospital & the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Mar 2026, 79 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 79 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2019
First posted
Jun 12, 2019
StartActual
Jul 29, 2019
Primary completionActual
Mar 25, 2026
CompletionActual
Mar 25, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03984097
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 12, 2019
Start date
Jul 29, 2019
Primary completion
Mar 25, 2026
Completion
Mar 25, 2026
Last update
Apr 9, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezagitamab

Start the discussion